The Effect of Intravenous L-kynurenine (LKYN) on Cerebral Hemodynamics in Healthy Volunteers
Primary Purpose
Headache
Status
Completed
Phase
Phase 1
Locations
Denmark
Study Type
Interventional
Intervention
L-kynurenine
Sponsored by
About this trial
This is an interventional other trial for Headache focused on measuring L-kynurenine, Cerebral hemodynamic, Headache, Mohammad Al-Mahdi Al-Karagholi
Eligibility Criteria
Inclusion Criteria:
- Healthy volunteers of both sexes.
- 18-60 years.
- 50-90 kg.
- Women of childbearing potential must use adequate contraception.
Exclusion Criteria:
- All primary headaches
- First-degree relative with migraine
- Headache less than 48 hours before the tests start
- Daily consumption of drugs of any kind other than oral contraceptives.
- Pregnant or nursing women. Cardiovascular disease of any kind, including cerebrovascular diseases.
Sites / Locations
- Rigshospitalet-Glostrup
Outcomes
Primary Outcome Measures
Velocity of MCA (VMCA)
Measured in MCA (middle cerebral artery) bilaterally with ultrasound (TCD) (2 Mhz, DWL)
The diameter of the STA (superficial temporal artery)
Measured by high-frequency ultrasound 12 of 29 (Derma Scan C, Cortex Technology, Denmark)
Headache
Headache declared orally on a verbal rating scale (VRS) 0-10. 0 represents no pain and 10 the worst possible headache.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03212430
Brief Title
The Effect of Intravenous L-kynurenine (LKYN) on Cerebral Hemodynamics in Healthy Volunteers
Official Title
The Effect of Intravenous L-kynurenine (LKYN) on Cerebral Hemodynamics in Healthy Volunteers
Study Type
Interventional
2. Study Status
Record Verification Date
January 2019
Overall Recruitment Status
Completed
Study Start Date
March 1, 2017 (Actual)
Primary Completion Date
January 20, 2019 (Actual)
Study Completion Date
January 20, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Danish Headache Center
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
To measure the cerebral hemodynamic effect of L-kynurenine.
Detailed Description
Aim: To investigate the physiological effect of L-Kynurenine after intravenous administration to healthy volunteers.
Hypothesis: L-kynurenine induces vasodilation in the cerebral vessels and trigger headache in healthy individuals.
Methods: 6 healthy volunteers will receive intravenous infusion of L-kynurenine using the following doses 50 microgram/kg, 100 microgram/kg, 150 microgram/kg, 300 microgram/kg, 500 microgram/kg, 1 mg/kg and 5 mg/kg over 20 min on 7 different days with at least 1 day in between. Before and after infusion (at 20, 40, 60, 80 and 100 min) we will record vital signs, circumferences of middle cerebral artery, superficial temporalis artery and headache intensity and characteristics.
The subjects will then have a questionnaire about headache for the following 24 hours.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Headache
Keywords
L-kynurenine, Cerebral hemodynamic, Headache, Mohammad Al-Mahdi Al-Karagholi
7. Study Design
Primary Purpose
Other
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Model Description
Pilot, Open label
Masking
ParticipantCare Provider
Allocation
Non-Randomized
Enrollment
6 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
L-kynurenine
Intervention Description
intravenous infusion of L-kynurenine to healthy individuals.
Primary Outcome Measure Information:
Title
Velocity of MCA (VMCA)
Description
Measured in MCA (middle cerebral artery) bilaterally with ultrasound (TCD) (2 Mhz, DWL)
Time Frame
Change from baseline VMCA at two hours after administration of L-kynurenine
Title
The diameter of the STA (superficial temporal artery)
Description
Measured by high-frequency ultrasound 12 of 29 (Derma Scan C, Cortex Technology, Denmark)
Time Frame
Change from baseline VMCA at two hours after administration of L-kynurenine
Title
Headache
Description
Headache declared orally on a verbal rating scale (VRS) 0-10. 0 represents no pain and 10 the worst possible headache.
Time Frame
occurrence of headache undtil 24 hours after infusion.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy volunteers of both sexes.
18-60 years.
50-90 kg.
Women of childbearing potential must use adequate contraception.
Exclusion Criteria:
All primary headaches
First-degree relative with migraine
Headache less than 48 hours before the tests start
Daily consumption of drugs of any kind other than oral contraceptives.
Pregnant or nursing women. Cardiovascular disease of any kind, including cerebrovascular diseases.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Messoud Ashina, Professor
Organizational Affiliation
Professor of neurology
Official's Role
Principal Investigator
Facility Information:
Facility Name
Rigshospitalet-Glostrup
City
Glostrup
State/Province
Nordre Ringvej 57
ZIP/Postal Code
2600
Country
Denmark
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
1. Using a controlled access approach, using a transparent and robust system to review requests and provide secure data access; 2. seeking consent for sharing IPD from trial participants in all future clinical trials with adequate assurance that patient privacy and confidentiality can be maintained; and 3. Establishing an approach to resource the sharing of IPD which would include support from trial funders, sponsor organisations and users of IPD
Learn more about this trial
The Effect of Intravenous L-kynurenine (LKYN) on Cerebral Hemodynamics in Healthy Volunteers
We'll reach out to this number within 24 hrs